157 related articles for article (PubMed ID: 15771766)
1. Infliximab and the bone in Crohn's disease.
Kunisaki R; Chaki O; Taguchi T; Sugiyama T; Sugita A
Aliment Pharmacol Ther; 2005 Mar; 21(6):789-90. PubMed ID: 15771766
[No Abstract] [Full Text] [Related]
2. Infliximab and the bone in Crohn's disease.
Franchimont N; Reenaers C; Louis E
Aliment Pharmacol Ther; 2005 Apr; 21(7):918-9. PubMed ID: 15801928
[No Abstract] [Full Text] [Related]
3. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
Franchimont N; Putzeys V; Collette J; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Franchimont D; Fiasse R; Pelckmans P; Malaise M; Belaiche J; Louis E
Aliment Pharmacol Ther; 2004 Sep; 20(6):607-14. PubMed ID: 15352908
[TBL] [Abstract][Full Text] [Related]
4. Infliximab in the management of the extra-intestinal manifestations of Crohn's disease.
Lawrance IC
J Gastroenterol Hepatol; 2004 Nov; 19(11):1332-3. PubMed ID: 15482549
[No Abstract] [Full Text] [Related]
5. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease.
Bernstein M; Irwin S; Greenberg GR
Am J Gastroenterol; 2005 Sep; 100(9):2031-5. PubMed ID: 16128948
[TBL] [Abstract][Full Text] [Related]
6. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
7. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
8. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the clinical use of infliximab in Crohn's disease.
Turner SM; Probert CS
Rom J Gastroenterol; 2003 Mar; 12(1):2-5. PubMed ID: 12673372
[No Abstract] [Full Text] [Related]
10. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
[No Abstract] [Full Text] [Related]
11. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.
Arnott ID; Shand A; Ghosh S
Am J Gastroenterol; 2000 Nov; 95(11):3326-7. PubMed ID: 11095380
[No Abstract] [Full Text] [Related]
12. Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
Diamanti A; Papadatou B; Knafelz D; Gambarara M; Ferretti F; Castro M
Am J Gastroenterol; 2003 Dec; 98(12):2812-3. PubMed ID: 14687847
[No Abstract] [Full Text] [Related]
13. Infliximab treatment in a patient with Crohn's disease on haemodialysis.
Kume K; Yamasaki M; Yoshikawa I; Harada M
Colorectal Dis; 2011 Mar; 13(3):341. PubMed ID: 20082632
[No Abstract] [Full Text] [Related]
14. A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab.
Papa A; Felice C; Marzo M; Guidi L
Am J Gastroenterol; 2010 Aug; 105(8):1904. PubMed ID: 20686472
[No Abstract] [Full Text] [Related]
15. [Infliximab--practical guidelines for the treatment of Crohn's disease].
Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
[TBL] [Abstract][Full Text] [Related]
16. Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis.
Persley K; Scherl E; Rubin P
Am J Gastroenterol; 2001 Dec; 96(12):3444-5. PubMed ID: 11774971
[No Abstract] [Full Text] [Related]
17. The Dutch guidelines for treatment with infliximab for Crohn's disease.
Vermeire S
Neth J Med; 2006; 64(7):210-1. PubMed ID: 16929081
[No Abstract] [Full Text] [Related]
18. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
19. Steroid-independent Crohn's disease patients also benefit from combination therapy of infliximab plus azathioprine.
van den Brande JM; Peppelenbosch MP; Hommes DW
Gastroenterology; 2006 Oct; 131(4):1362-3. PubMed ID: 17030216
[No Abstract] [Full Text] [Related]
20. Anti-Saccharomyces cerevisiae antibodies and response to infliximab in refractory Crohn's disease.
Schröder O; Naumann M; Stein J
Aliment Pharmacol Ther; 2004 Oct; 20(7):823-4. PubMed ID: 15379845
[No Abstract] [Full Text] [Related]
[Next] [New Search]
